|
Nov 3
|
Codexis, Inc. (NASDAQ:CDXS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.17
|
|
Nov 2
|
Codexis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Nov 1
|
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ...
|
|
Nov 1
|
Promising Penny Stocks On US Exchanges In November 2024
|
|
Oct 31
|
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
|
|
Oct 31
|
Codexis: Q3 Earnings Snapshot
|
|
Oct 31
|
Codexis Reports Third Quarter 2024 Financial Results
|
|
Oct 24
|
Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
|
|
Oct 15
|
Codexis announces employment inducement grants
|
|
Oct 14
|
Codexis Announces New Employment Inducement Grants
|
|
Oct 10
|
Codexis to Report Third Quarter 2024 Financial Results on October 31
|
|
Oct 9
|
Codexis Inc (CDXS) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
|
|
Oct 2
|
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
|
|
Oct 1
|
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
|
|
Sep 3
|
Codexis to Participate in Upcoming Healthcare Conferences
|
|
Jan 14
|
The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable
|